Telix Investors Face Jan. 9 Deadline in Securities Class Action Tied to SEC, FDA Disclosures

Plaintiff firms are pressing affected shareholders to seek lead-plaintiff status before the court’s cutoff.

Overview

Multiple law firms report a federal securities class action on behalf of investors who bought Telix securities between Feb. 21 and Aug. 28, 2025.
Complaints allege Telix overstated progress on prostate cancer therapeutics and overstated the quality and compliance of third‑party manufacturing partners.
Telix disclosed an SEC subpoena on July 22, 2025 regarding its development disclosures, after which ADSs fell more than 13% over two sessions, according to the filings.
On Aug. 28, 2025 the company reported an FDA Complete Response Letter for TLX250-CDx citing CMC deficiencies and Form 483s at two third‑party sites, with ADSs dropping over 21% across two sessions.
Filings note the case is pending in the Southern District of Indiana and investor notices from Faruqi & Faruqi, Berger Montague, Hagens Berman, Bragar Eagel & Squire, and Portnoy Law highlight the Jan. 9, 2026 lead‑plaintiff deadline.